The Kirros study is actively enrolling patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (HCC) with Child-Pugh B7 or B8 cirrhosis. The study will be evaluating the safety and efficacy of first-line treatment options. Trial locations are available nationwide. Consider referring your eligible patients. #LiverCancer #HepatocellularCarcinoma #HCCresearch https://lnkd.in/gCHsSEez
关于我们
The official Genentech Medical LinkedIn page for sharing the latest scientific, medical, and clinical trial information with US healthcare professionals. ? By interacting with this LinkedIn page, you confirm that you are a US healthcare professional. ? There are regulations that govern our LinkedIn page. We reserve the right to engage with posts that follow our community guidelines (https://bit.ly/4aqwv2h). Not all posts will receive responses. Responses will be provided during business hours M-F, 5am to 5pm PT. ? This page provides a platform for Genentech Medical Affairs to share scientific information, disease education, and clinical trial updates. We welcome your comments. Please stay on topic and refrain from using inappropriate language. ? If you are aware of anyone that has experienced any adverse events related to a Genentech product, report them immediately to Genentech Drug Safety by emailing [email protected] or calling 1-888-835-2555. You can also contact the FDA directly by visiting www.fda.gov/medwatch or calling 1-800-FDA-1088. We will report this adverse event to the FDA and may contact you with questions or request additional information. ? Respect others’ privacy and do not share personal information that is not in the public domain. ? Do not reference Genentech products and services or alternative therapeutic options or your posts may be deleted. ? This page is for informational purposes only and is not a forum to solicit or give medical advice. ? The sharing of content or links to third-party sites is not an indication of endorsement by Genentech and Genentech is not responsible for this content. ? If you have a medical inquiry, contact our Medical Information team M-F, 5am to 5pm PT by calling 1-800-821-8590.
- 网站
-
https://www.genentech-medinfo.com/
Genentech Medical的外部链接
- 所属行业
- 生物技术研究
- 规模
- 超过 10,001 人
动态
-
Patients with hepatocellular carcinoma (HCC) and moderately impaired liver function are often excluded from systemic therapy clinical trials. The Kirros study, developed specifically for HCC patients with Child-Pugh B7 or B8 cirrhosis, is actively enrolling patients with unresectable, locally advanced or metastatic HCC. The study will be evaluating the safety and efficacy of first-line treatment options. Consider referring your eligible patients. #LiverCancer #HepatocellularCarcinoma #HCCresearch https://lnkd.in/g3GXrcAM
-
Missed us at #ACR24? View our latest research in #rheumatology and #lupus #nephritis by visiting MEDICALLY, our online platform for scientific exchange, congress information, and resources. https://lnkd.in/gufQ2dpz
-
-
ENROLLING NOW: The Phase III pionERA clinical trial is actively enrolling patients with ER+, HER2-, endocrine-resistant breast cancer. This trial seeks to evaluate the efficacy and safety of a first-line oral SERD against an intramuscular SERD, both combined with a CDK4/6 inhibitor of choice. ? Find a pionERA clinical trial site near you: https://lnkd.in/gx8MD9GZ ? Contact the Genentech US Trial Information Support Team (TISL) here to learn more: https://lnkd.in/gf9PGj32 ? #CancerResearch #Oncology #ClinicalTrial
-
Despite recent advances in the treatment of breast cancer, patients with ER+, HER2-, endocrine-resistant breast cancer continue to fall through the gaps. The Phase III pionERA trial seeks to address this unmet need by evaluating an oral SERD against an intramuscular SERD, both combined with a CDK4/6 inhibitor of choice in patients with advanced endocrine-resistant ER+, HER2- breast cancer, with or without an ESR1 mutation. ? Learn how to enroll eligible patients in pionERA: https://lnkd.in/g7pCQvzQ ? #CancerResearch #Oncology #ClinicalTrial
-
New Publication: Results from the primary analysis of the Phase III STARGLO study investigating a bispecific antibody combination regimen vs standard chemoimmunotherapy in patients with relapsed/refractory #DLBCL. Read the article in The Lancet to learn more #hematology #oncology https://lnkd.in/guA2FGKN
-
Missed us at #GOLDCOPD2024? View our #pulmonology research by visiting MEDICALLY, our online platform for scientific exchange, congress information and resources. #COPD https://lnkd.in/g9hehkX5
-
-
Join us at #ACR24 to hear about the latest advancements in #rheumatology and #lupus #nephritis. Have questions or insights you would like to discuss? Visit our Medical Affairs team at booth 2819. https://lnkd.in/eNxSd_km
-
You are invited! Visit our Learning Lab at #GOLDCOPD2024 to explore the role of ST2 and the IL-33 pathway in #COPD inflammation, meet experts in #pulmonology, and check out emerging research. https://lnkd.in/guhjxBxF
-
Join Genentech at #GOLDCOPD2024 to hear the latest data in #pulmonology and #COPD. Have questions or insights you would like to discuss? Visit our Medical Affairs team at booth 24. https://lnkd.in/guhjxBxF